The neurobehavioral pharmacology of ketamine: Implications for drug abuse, addiction, and psychiatric disorders

ILAR Journal

Volumn 52, Issue 3, 2011, Pages 366-378

  Trujillo, Keith A ^a   Smith, Monique L ^a,b   Sullivan, Brian ^a,c   Heller, Colleen Y ^a   Garcia, Cynthia ^a,d   Bates, Melvin ^a,e  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Analgesia; Anesthesia; Animal model; Antide pressant; Drug abuse; Glutamate; Ketamine; Reward; Schizo phrenia

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; KETAMINE;

ADDICTION; ANIMAL; DRUG DEPENDENCE; HUMAN;

ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ADDICTIVE; HUMANS; KETAMINE; SUBSTANCE-RELATED DISORDERS;

EID: 84873476824     PISSN: 10842020     EISSN: 19306180     Source Type: Journal    
DOI: 10.1093/ilar.52.3.366     Document Type: Article

References (166)

1. Adams B, Moghaddam B. 1998. Corticolimbic dopamine neurotransmis-sion is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554.
2. Adams BW, Moghaddam B. 2001. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 50:750-757.
3. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. 1998. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43:811-816.
4. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A. 1999. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649.
5. Amann B, Born C, Crespo JM, Pomarol-Clotet E, McKenna P. 2010. Lamotrigine: When and where does it act in affective disorders? A systematic review. J Psychopharmacol (Sep 7; epub ahead of print).
6. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. 2000. Attenuation of the neuropsychiatric effects of ke amine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57:270-276.
7. Angrist B, Sathananthan G, Wilk S, Gershon S. 1974. Amphetamine psychosis: Behavioral and biochemical aspects. J Psychiatr Res 11:13-23.
8. Anis NA, Berry SC, Burton NR, Lodge D. 1983. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by n-methyl-aspartate. Br J Pharmacol 79:565-575.
9. Baker AK, Hoffmann VL, Meert TF. 2002. Interactions of NMDA antagonists and an alpha 2 agonist with mu, delta and kappa opioids in an acute nociception assay. Acta Anaesthesiol Belg 53:203-212.
10. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. 2003. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:687-700.
11. Bell RF. 2009. Ketamine for chronic non-cancer pain. Pain 141:210-214.
12. Bell RF, Eccleston C, Kalso E. 2003. Ketamine as adjuvant to opioids for cancer pain: A qualitative systematic review. J Pain Symptom Manage 26:867-875.
13. Bell RF, Dahl JB, Moore RA, Kalso E. 2005. Peri-operative ketamine for acute post-operative pain: A quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 49:1405-1428.
14. Bergman SA. 1999. Ketamine: Review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 46:10-20.
15. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
16. Bozarth MA, ed. 1987. Methods of Assessing the Reinforcing Properties of Abused Drugs. New York: Springer-Verlag.
17. Broadbear JH, Winger G, Woods JH. 2004. Self-administration of fentanyl, cocaine and ketamine: Effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology (Berl) 176:398-406.
18. Brody SA, Geyer MA, Large CH. 2003. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169:240-246.
19. Carroll ME, Stotz DC. 1983. Oral d-amphetamine and ketamine self-administration by rhesus monkeys: Effects of food deprivation. J Pharmacol Exp Ther 227:28-34.
20. Castellani S, Adams PM. 1981. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 73:143-154.
21. Cilia J, Hatcher P, Reavill C, Jones DN. 2007. (+/-) ketamine-induced pre-pulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol 21:302-311.
22. Collingridge GL, Watkins JC, eds. 1995. The NMDA Receptor. New York: Oxford University Press.
23. Collins GT, Woods JH. 2007. Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat. J Pharmacol Exp Ther 323:599-605.
24. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR. 1984. Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology (Berl) 82:6-13.
25. Craven R. 2007. Ketamine. Anaesthesia 62 Suppl 1:48-53.
26. Dambisya YM, Lee TL. 1994. Antinociceptive effects of ketamine-opioid combinations in the mouse tail flick test. Methods Find Exp Clin Pharmacol 16:179-184.
27. Davies BM, Beech HR 1960. The effect of 1-arylcylohexylamine (sernyl) on twelve normal volunteers. J Ment Sci 106:912-924.
28. DEA [Drug Enforcement Administration]. 1999. News release: DEA to control "Special K" for the first time. Available online (www.usdoj.gov:80/dea/pubs/pressrel/pr071399.htm), accessed on October 14, 2011.
29. De Luca MT, Badiani A. 2011. Ketamine self-administration in the rat: Evidence for a critical role of setting. Psychopharmacology (Berl) 214:549-556.
30. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr. 2010. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71:1605-1611.
31. Dillon P, Copeland J, Jansen K. 2003. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 69:23-28.
32. Domino EF, ed. 1990. Status of Ketamine in Anesthesiology. Ann Arbor: NPP Books.
33. Domino EF. 2010. Taming the ketamine tiger. Anesthesiology 113:678-684.
34. Domino EF, Chodoff P, Corssen G. 1965. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 6:279-291.
35. Douglas BG, Dagirmanjian R. 1975. The effects of magnesium deficiency of ketamine sleeping times in the rat. Br J Anaesth 47:336-340.
36. Fantegrossi WE, Murnane KS, Reissig CJ. 2008. The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17-33.
37. Farber NB, Jiang XP, Heinkel C, Nemmers B. 2002a. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 7:726-733.
38. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. 2002b. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7:32-43.
39. Freese TE, Miotto K, Reback CJ. 2002. The effects and consequences of selected club drugs. J Subst Abuse Treat 23:151-156.
40. Gao C, Che LW, Chen J, Xu XJ, Chi ZQ. 2003. Ohmefentanyl stereoisomers induce changes of CREB phosphorylation in hippocampus of mice in conditioned place preference paradigm. Cell Res 13:29-34.
41. Garcia C, Trujillo KA. 2007. Club drug interactions: Effects of ketamine and methamphetamine combinations on locomotor behavior in rats. Soc Neurosci Annu Conf Abstr #813.15.
42. Gill JR, Stajic M. 2000. Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci 45:655-658.
43. Gilmour G, Pioli EY, Dix SL, Smith JW, Conway MW, Jones WT, Loomis S, Mason R, Shahabi S, Tricklebank MD. 2009. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: Implications for "NMDA antagonist modeling" of schizophrenia. Psychopharmacology (Berl) 205:203-216.
44. Goff DC. 2009. Review: Lamotrigine may be an effective treatment for clo-zapine resistant schizophrenia. Evid Based Ment Health 12:111.
45. Haas DA, Harper DG. 1992. Ketamine: A review of its pharmacologic prop-erties and use in ambulatory anesthesia. Anesth Prog 39:61-68.
46. Hance AJ, Winters WD, Quam DD, Benthuysen JL, Cadd GG. 1989. Cata-lepsy induced by combinations of ketamine and morphine: Potentiation, antagonism, tolerance and cross-tolerance in the rat. Neuropharmacol-ogy 28:109-116.
47. Hashimoto K. 2009. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105-123.
48. Hauber W, Andersen R. 1993. The non-NMDA glutamate receptor antago-nist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn Schmie-debergs Arch Pharmacol 348:486-490.
49. Hauber W, Waldenmeier MT. 1994. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA re-ceptor antagonist CGP 37849. Eur J Pharmacol 256:339-342.
50. Heller CY, Trujillo KA. 2007. Sensitization to ketamine ("Special K"): Ef-fects of injection interval and environmental conditioning. Soc Neurosci Annu Conf Abstr #813.3.
51. Hocking G, Cousins MJ. 2003. Ketamine in chronic pain management: An evidence-based review. Anesth Analg 97:1730-1739.
52. Hoffmann VL, Baker AK, Vercauteren MP, Adriaensen HF, Meert TF. 2003. Epidural ketamine potentiates epidural morphine but not fentanyl in acute nociception in rats. Eur J Pain 7:121-130.
53. Holtman JR, Jing X, Wala EP. 2003. Sex-related differences in the enhance-ment of morphine antinociception by NMDA receptor antagonists in rats. Pharmacol Biochem Behav 76:285-293.
54. Imre G, Fokkema DS, Den Boer JA, Ter Horst GJ. 2006. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 69:338-345.
55. Janowsky DS, Risch C. 1979. Amphetamine psychosis and psychotic symp-toms. Psychopharmacology 65:73-77.
56. Jansen KL. 1993. Non-medical use of ketamine. BMJ 306:601-602.
57. Jansen KL. 2000. A review of the nonmedical use of ketamine: Use, users and consequences. J Psychoact Drugs 32:419-433.
58. Jansen KL, Darracot-Cankovic R. 2001. The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoact Drugs 33:151-158.
59. Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencycli-dine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
60. Joo G, Horvath G, Klimscha W, Kekesi G, Dobos I, Szikszay M, Benedek G. 2000. The effects of ketamine and its enantiomers on the morphine-or dexmedetomidine-induced antinociception after intrathecal adminis-tration in rats. Anesthesiology 93:231-241.
61. Kelly BC, Parsons JT, Wells BE. 2006. Prevalence and predictors of club drug use among club-going young adults in New York City. J Urban Health 83:884-895.
62. Kosson D, Klinowiecka A, Kosson P, Bonney I, Carr DB, Mayzner-Zawadzka E, Lipkowski AW. 2008. Intrathecal antinociceptive interac-tion between the NMDA antagonist ketamine and the opioids, morphine and biphalin. Eur J Pain 12:611-616.
63. Kronenberg, RH. 2002. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Pallia-tive Care Pharmacother 16:27-35.
64. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psy-chotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
65. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS. 1999. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145:193-204.
66. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. 2003. NMDA receptor antagonist effects, cortical glutamatergic func-tion, and schizophrenia: Toward a paradigm shift in medication devel-opment. Psychopharmacology (Berl) 169:215-233.
67. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. 2005a. Pre-liminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pre-treatment with the group II metabotropic glutamate receptor agonist, ly354740, in healthy human subjects. Psychopharmacology (Berl) 179:303-309.
68. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D'Souza DC. 2005b. Comparative and interactive human psychopharmacologic ef-fects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psy-chiatry 62:985-994.
69. Kugaya A, Sanacora G. 2005. Beyond monoamines: Glutamatergic func-tion in mood disorders. CNS Spectr 10:808-819.
70. Lahti AC, Koffel B, LaPorte D, Tamminga CA. 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharma-cology 13:9-19.
71. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neu-ropsychopharmacology 25:455-467.
72. Lannes B, Micheletti G, Warter JM, Kempf E, Di Scala G. 1991. Behav-ioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci Lett 128:177-181.
73. Large CH, Webster EL, Goff DC. 2005. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 181:415-436.
74. Latremoliere A, Woolf CJ. 2009. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain 10:895-926.
75. Leccese AP, Marquis KL, Mattia A, Moreton JE. 1986. The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats. Behav Brain Res 22:257-264.
76. Lees J, Hallak JE, Deakin JF, Dursun SM. 2004. Gender differences and the effects of ketamine in healthy volunteers. J Psychopharmacol 18:337-339.
77. Leri F, Bruneau J, Stewart J. 2003. Understanding polydrug use: Review of heroin and cocaine co-use. Addiction 98:7-22.
78. Li F, Fang Q, Liu Y, Zhao M, Li D, Wang J, Lu L. 2008. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats. Eur J Pharmacol 589:122-126.
79. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
80. Livingston A, Waterman AE. 1978. The development of tolerance to ket-amine in rats and the significance of hepatic metabolism. Br J Pharma-col 64:63-69.
81. Lodge D, Anis NA, Burton NR. 1982. Effects of optical isomers of ket-amine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neurosci Lett 29:281-286.
82. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. 2003a. Ef-fects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist ly379268. Neuroscience 117:697-706.
83. Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, Vernier JM, Bristow LJ. 2003b. Group II MGLU receptor activation suppresses nor-epinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28:1622-1632.
84. Lourenço Da Silva A, Hoffmann A, Dietrich MO, Dall'Igna OP, Souza DO, Lara DR. 2003. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 48:27-30.
85. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. 1959. Study of a new schizophrenomimetic drug, sernyl. AMA Arch Neurol Psychiatry 81:363-369.
86. Lukas SE, Griffiths RR, Brady JV, Wurster RM. 1984. Phencyclidine-ana-logue self-injection by the baboon. Psychopharmacology (Berl) 83:316-320.
87. Machado-Vieira R, Manji HK, Zarate CA. 2009. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15:525-539.
88. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK. 2008. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propi-onic acid receptors. Biol Psychiatry 63:349-352.
89. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. 1997a. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 42:664-668.
90. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. 1997b. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsy-chopharmacology 17:141-150.
91. Mansbach RS, Geyer MA. 1991. Parametric determinants in pre-stimulus modification of acoustic startle: Interaction with ketamine. Psychophar-macology (Berl) 105:162-168.
92. Mansbach RS, Carver J, Zorn SH. 2001. Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Bio-chem Behav 69:535-542.
93. Mao J. 1999. NMDA and opioid receptors: Their interactions in antinocicep-tion, tolerance and neuroplasticity. Brain Res Rev 30:289-304.
94. Marquis KL, Moreton JE. 1987. Animal models of intravenous phencycli-noid self-administration. Pharmacol Biochem Behav 27:385-389.
95. Marquis KL, Gussio R, Webb MG, Moreton JE. 1989. Cortical EEG changes during the self-administration of phencyclinoids. Neurophar-macology 28:1193-1198.
96. Mathew SJ, Manji HK, Charney DS. 2008. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33:2080-2092.
97. McCarthy DA, Harrigan SE. 1977. Dependence-producing capacity of ketamine in macaca mulatta. In: Hülz E, Sanchez-Hernandez JA, Vasconcelos G, Lunn JN. Anaesthesiology: Proceedings of the VI World Congress of Anaesthesiology, Mexico City, April 24-30, 1976. Amster-dam: Excerpta Medica. p 160-168.
98. McCarthy DA, Chen G, Kaump DH, Ensor C. 1965. General anesthetic and other pharmacological properties of 2-(o-chlorophenyl)-2-methylamino cyclohexanone HCL (CI-581). J New Drugs 28:21-33.
99. Mercado E, Garcia C, Trujillo KA. 2009. Low dose depressant effects of ketamine and interaction with other drugs of abuse. Soc Neurosci Ann Conf Abstr #551.17.
100. Moghaddam B, Adams BW. 1998. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352.
101. Moghaddam B, Adams B, Verma A, Daly D. 1997. Activation of gluta-matergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disrup-tions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
102. Moreton JE, Meisch RA, Stark L, Thompson T. 1977. Ketamine self-administration by the rhesus monkey. J Pharmacol Exp Ther 203:303-309.
103. Mucha RF, van der Kooy D, O'Shaughnessy M, Bucenieks P. 1982. Drug reinforcement studied by the use of place conditioning in rat. Brain Res 243:91-105.
104. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. 2008. Journey through the k-hole: Phenomenological aspects of ket-amine use. Drug Alcohol Depend 95:219-229.
105. Nadeson R, Tucker A, Bajunaki E, Goodchild CS. 2002. Potentiation by ketamine of fentanyl antinociception. I. An experimental study in rats showing that ketamine administered by non-spinal routes targets spinal cord antinociceptive systems. Br J Anaesth 88:685-691.
106. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK. 2010 Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor an-tagonism. Pharmacol Ther 128:419-432.
107. Nelson CL, Burk JA, Bruno JP, Sarter M. 2002. Effects of acute and re-peated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. Psychopharmacol-ogy (Berl) 161:168-179.
108. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW. 1999. Ketamine-induced NMDA recep-tor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106-118.
109. Olney JW, Newcomer JW, Farber NB. 1999. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
110. Ong JC, Brody SA, Large CH, Geyer MA. 2005. An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther 315:1163-1171.
111. Paul IA, Skolnick P. 2003. Glutamate and depression: Clinical and preclini-cal studies. Ann N Y Acad Sci 1003:250-272.
112. Pellissier T, Laurido C, Kramer V, Hernandez A, Paelle C. 2003. Antinoci-ceptive interactions of ketamine with morphine or methadone in monon-europathic rats. Eur J Pharmacol 477:23-28.
113. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. 2008. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22:761-786.
114. Popik P, Kos T, Sowa-Kucma M, Nowak G. 2008. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 198:421-430.
115. Premkumar TS, Pick J. 2006. Lamotrigine for schizophrenia. Cochrane Da-tabase Syst Rev:CD005962.
116. Razoux F, Garcia R, Lena I. 2007. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic effi-cacy and glutamate release in the nucleus accumbens. Neuropsycho-pharmacology 32:719-727.
117. Risner ME. 1982. Intravenous self-administration of phencyclidine and re-lated compounds in the dog. J Pharmacol Exp Ther 221:637-644.
118. Robinson TE, Berridge KC. 1993. The neural basis of drug craving: An in-centive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247-291.
119. Robinson TE, Berridge KC. 2001. Incentive-sensitization and addiction. Addiction 96:103-114.
120. Robinson TE, Berridge KC. 2002. Addiction. Annu Rev Psychol 14:14.
121. Rocha BA, Ward AS, Egilmez Y, Lytle DA, Emmett-Oglesby MW. 1996. Tolerance to the discriminative stimulus and reinforcing effects of ket-amine. Behav Pharmacol 7:160-168.
122. Ross S. 2008. Ketamine and addiction. Primary Psychiatry 15:61-69.
123. Schatzberg AF, Nemeroff CB, eds. 2009. Textbook of Psychopharmacol-ogy. Arlington VA: American Psychiatric Publishing.
124. Seeman P. 2009. Glutamate and dopamine components in schizophrenia. J Psychiatr Neurosci 34:143-149.
125. Sinner B, Graf BM. 2008. Ketamine. Handb Exp Pharmacol:313-333.
126. Skolnick P. 1999. Antidepressants for the new millennium. Eur J Pharmacol 375:31-40.
127. Skolnick P, Popik P, Trullas R. 2009. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563-569.
128. Smith KM, Larive LL, Romanelli F. 2002. Club drugs: Methylene-dioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 59:1067-1076.
129. Subramaniam K, Subramaniam B, Steinbrook RA. 2004. Ketamine as adju-vant analgesic to opioids: A quantitative and qualitative systematic re-view. Anesth Analg 99:482-495, table of contents.
130. Sullivan B, Trujillo KA. 2007. Sensitization to ketamine in a "bump" model: Robust effect following different patterns of administration. Soc Neuro-sci Ann Conf Abstr #813.13.
131. Sullivan B, Trujillo KA. 2010. Modest motivational effects of ketamine as demonstrated by conditioned place preference. Soc Neurosci Ann Conf Abstr #67.17.
132. Suzuki T, Aoki T, Kato H, Yamazaki M, Misawa M. 1999. Effects of the 5-ht(3) receptor antagonist ondansetron on the ketamine-and dizo-cilpine-induced place preferences in mice. Eur J Pharmacol 385:99-102.
133. Suzuki T, Kato H, Aoki T, Tsuda M, Narita M, Misawa M. 2000. Effects of the non-competitive NMDA receptor antagonist ketamine on morphine-induced place preference in mice. Life Sci 67:383-389.
134. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA. 1998. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 140:75-80.
135. Takahata R, Moghaddam B. 2003. Activation of glutamate neurotransmis-sion in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28:1117-1124.
136. Trujillo KA. 2000. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. Psychophar-macology (Berl) 151:121-141.
137. Trujillo KA, Akil H. 1991. Inhibition of morphine tolerance and depen-dence by the NMDA receptor antagonist MK-801. Science 251:85-87.
138. Trujillo KA, Akil H. 1994. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brain Res 633:178-188.
139. Trujillo KA, Herman JP, Schäfer MK-H, Mansour A, Meador-Woodruff J, Watson SJ, Akil H. 1993. Drug reward and brain circuitry: Recent advances and future directions. In: Korenman SG, Barchas JD. Biological Basis of Substance Abuse. New York: Oxford University Press. p 119-142.
140. Trujillo KA, Zamora JJ, Warmoth KP. 2008. Increased response to ketamine following treatment at long intervals: Implications for intermittent use. Biol Psychiatry 63:178-183.
141. Tzschentke TM. 1998. Measuring reward with the conditioned place prefer-ence paradigm: A comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56:613-672.
142. Tzschentke TM. 2007. Measuring reward with the conditioned place prefer-ence (CPP) paradigm: Update of the last decade. Addict Biol 12:227-462.
143. Uchihashi Y, Kuribara H, Morita T, Fujita T. 1993. The repeated administra-tion of ketamine induces an enhancement of its stimulant action in mice. Jpn J Pharmacol 61:149-151.
144. Uzbay IT, Wallis CJ, Lal H, Forster MJ. 2000. Effects of NMDA receptor blockers on cocaine-stimulated locomotor activity in mice. Behav Brain Res 108:57-61.
145. van Berckel BN, Oranje B, van Ree JM, Verbaten MN, Kahn RS. 1998. The effects of low dose ketamine on sensory gating, neuroendocrine secre-tion and behavior in healthy human subjects. Psychopharmacology (Berl) 137:271-281.
146. van der Kam EL, de Vry J, Tzschentke TM. 2007. Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat. Behav Pharmacol 18:717-724.
147. van der Kam EL, De Vry J, Tzschentke TM. 2009a. 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates ketamine and heroin re-ward as assessed by acquisition, extinction, and reinstatement of conditioned place preference in the rat. Eur J Pharmacol 606:94-101.
148. van der Kam EL, De Vry J, Tzschentke TM. 2009b. The mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) supports intra-venous self-administration and induces conditioned place preference in the rat. Eur J Pharmacol 607:114-120.
149. Visser E, Schug SA. 2006. The role of ketamine in pain management. Biomed Pharmacother 60:341-348.
150. White JM, Ryan CF. 1996. Pharmacological properties of ketamine. Drug Alcohol Rev 15:145-155.
151. White PF, Way WL, Trevor AJ. 1982. Ketamine: Its pharmacology and therapeutic uses. Anesthesiology 56:119-136.
152. Wiley JL, Evans RL, Grainger DB, Nicholson KL. 2008. Age-dependent differences in sensitivity and sensitization to cannabinoids and "club drugs" in male adolescent and adult rats. Addict Biol 13:277-286.
153. Williams HJ, Zamzow CR, Robertson H, Dursun SM. 2006. Effects of clo-zapine plus lamotrigine on phencyclidine-induced hyperactivity. Prog Neuropsychopharmacol Biol Psychiatry 30:239-243.
154. Winger G, Palmer RK, Woods JH. 1989. Drug-reinforced responding: Rapid determination of dose-response functions. Drug Alcohol Depend 24:135-142.
155. Winters WD, Hance AJ, Cadd GG, Quam DD, Benthuysen JL. 1988. Ket-amine-and morphine-induced analgesia and catalepsy. I. Tolerance, cross-tolerance, potentiation, residual morphine levels and naloxone ac-tion in the rat. J Pharmacol Exp Ther 244:51-57.
156. Wise RA. 1988. Psychomotor stimulant properties of addictive drugs. Ann N Y Acad Sci 537:228-234.
157. Wise RA, Bozarth MA. 1987. A psychomotor stimulant theory of addiction. Psychol Rev 94:469-492.
158. Wolff K, Winstock AR. 2006. Ketamine: From medicine to misuse. CNS Drugs 20:199-218.
159. Wood PL, Rao TS, Iyengar S, Lanthorn T, Monahan J, Cordi A, Sun E, Vazquez M, Gray N, Contreras P. 1990. A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/glycine/ion channel receptor macrocomplex. Neurochem Res 15:217-230.
160. Woolf CJ. 2011. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 152(3 Suppl):S2-S15.
161. Xu DD, Mo ZX, Yung KK, Yang Y, Leung AW. 2006. Individual and com-bined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats. Neurosignals 15:322-331.
162. Yamakura T, Shimoji K. 1999. Subunit-and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 59:279-298.
163. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. 2002. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 71:341-344.
164. Young AM, Woods JH. 1981. Maintenance of behavior by ketamine and related compounds in rhesus monkeys with different self-administration histories. J Pharmacol Exp Ther 218:720-727.
165. Zarate CA, Manji HK. 2008. Riluzole in psychiatry: A systematic review of the literature. Expert Opin Drug Metab Toxicol 4:1223-1234.
166. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.